MA29836B1 - FUSION PROTEINS WITH ALBUMIN - Google Patents

FUSION PROTEINS WITH ALBUMIN

Info

Publication number
MA29836B1
MA29836B1 MA30727A MA30727A MA29836B1 MA 29836 B1 MA29836 B1 MA 29836B1 MA 30727 A MA30727 A MA 30727A MA 30727 A MA30727 A MA 30727A MA 29836 B1 MA29836 B1 MA 29836B1
Authority
MA
Morocco
Prior art keywords
fusion proteins
albumin fusion
albumin
vectors
host cells
Prior art date
Application number
MA30727A
Other languages
French (fr)
Inventor
Adam Bell
Paul Moore
Yanggu Shi
David Lafleur
Michael Laird
Craig Rosen
William Haseltine
Douglas Woods
Jason Bock
Mani Subramanian
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of MA29836B1 publication Critical patent/MA29836B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention englobe des protéines de fusion d'albumine. Les molécules d'acides nucléiques codant pour les protéines de fusion d'albumine de l'invention sont également englobées par l'invention, de même que les vecteurs contenant ces acides nucléiques, les cellules hôtes transformées avec ces vecteurs d'acides nucléiques, et les procédés de fabrication des protéines de fusion d'albumine de l'invention et utilisant ces acides nucléiques, vecteurs, et/ou cellules hôtes. De plus, la présente invention comprend des compositions pharmaceutiques comprenant les protéines de fusion d'albumine et les procédés de traitement, de prévention, ou d'amélioration de maladies, troubles pathologies utilisant les protéines de fusion d'albumine de l'invention.The present invention encompasses albumin fusion proteins. The nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acid vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and / or host cells. In addition, the present invention includes pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating disease, pathological conditions using the albumin fusion proteins of the invention.

MA30727A 2005-08-12 2008-03-07 FUSION PROTEINS WITH ALBUMIN MA29836B1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US70752105P 2005-08-12 2005-08-12
US71238605P 2005-08-31 2005-08-31
US73272405P 2005-11-03 2005-11-03
US77691406P 2006-02-28 2006-02-28
US78136106P 2006-03-13 2006-03-13
US81018206P 2006-06-02 2006-06-02
US81368206P 2006-06-15 2006-06-15

Publications (1)

Publication Number Publication Date
MA29836B1 true MA29836B1 (en) 2008-10-03

Family

ID=37758042

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30727A MA29836B1 (en) 2005-08-12 2008-03-07 FUSION PROTEINS WITH ALBUMIN

Country Status (13)

Country Link
EP (1) EP1924596A4 (en)
JP (1) JP2009504157A (en)
KR (1) KR20080071119A (en)
AU (1) AU2006280312A1 (en)
BR (1) BRPI0614761A2 (en)
CA (1) CA2618476A1 (en)
EC (1) ECSP088262A (en)
IL (1) IL189246A0 (en)
MA (1) MA29836B1 (en)
MX (1) MX2008001865A (en)
NO (1) NO20081233L (en)
TN (1) TNSN08064A1 (en)
WO (1) WO2007021494A2 (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP2267026A1 (en) 2000-04-12 2010-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
PT1463751E (en) 2001-12-21 2013-08-26 Human Genome Sciences Inc Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
PL1729795T3 (en) 2004-02-09 2016-08-31 Human Genome Sciences Inc Albumin fusion proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
BRPI0712383A2 (en) 2006-06-07 2012-07-10 Human Genome Sciences Inc albumin fusion proteins
US20100254944A1 (en) * 2006-09-14 2010-10-07 Mani Subramanian Albumin Fusion Proteins
EP2423221B1 (en) 2007-01-30 2015-04-29 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
US20110293557A1 (en) 2008-06-13 2011-12-01 Proyecto De Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds
CN102378635A (en) * 2009-01-16 2012-03-14 特瓦制药工业有限公司 Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia
US9493545B2 (en) 2009-02-11 2016-11-15 Albumedix A/S Albumin variants and conjugates
KR20100100254A (en) * 2009-03-05 2010-09-15 (주)바이오큐어팜 Composition for preventing or treating cancer comprising human serum albumin-timp-2 fusion protein and anti-cancer agent
WO2011028229A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
EP3421491A3 (en) 2009-10-30 2019-03-27 Albumedix Ltd Albumin variants
JP5969458B2 (en) 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ Albumin derivatives and variants
BR112012029611A2 (en) 2010-05-21 2017-07-25 Merrimack Pharmaceuticals Inc bispecific fusion protein, pharmaceutical composition, method of treating tissue damage in an individual, method of promoting tissue regeneration or survival in an individual, and nucleic acid molecule
JP5948683B2 (en) * 2011-02-28 2016-07-06 国立研究開発法人国立循環器病研究センター Medicament for inhibiting malignant tumor metastasis
US8822417B2 (en) 2011-05-05 2014-09-02 Novozymes Biopharma DIC A/S Albumin variants
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
AU2012267484B2 (en) 2011-06-10 2017-03-23 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104383541A (en) 2011-10-21 2015-03-04 艾伯维公司 Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
DK2583680T1 (en) 2011-10-21 2015-01-19 Abbvie Inc Mono (PSI-7977), or combination treatment of DAA for use in the treatment of HCV
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
LT2804623T (en) 2012-01-12 2019-12-10 Bioverativ Therapeutics Inc Chimeric factor viii polypeptides and uses thereof
HUE043537T2 (en) 2012-02-15 2019-08-28 Bioverativ Therapeutics Inc Recombinant factor viii proteins
RS63870B1 (en) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Factor viii compositions and methods of making and using same
BR112014018679A2 (en) 2012-03-16 2017-07-04 Novozymes Biopharma Dk As albumin variants
JP2015525222A (en) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Chimeric coagulation factor
JP2015521589A (en) 2012-06-08 2015-07-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Procoagulant compounds
CN103525695B (en) * 2012-07-04 2015-05-20 长沙中生众捷生物技术有限公司 Portable kidney function detecting system
LT2882450T (en) 2012-07-11 2020-03-25 Bioverativ Therapeutics Inc. Factor viii complex with xten and von willebrand factor protein, and uses thereof
CA2888806A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
BR112015010318A2 (en) 2012-11-08 2017-08-22 Albumedix As ALBUMIN VARIANTS
RS61387B1 (en) 2013-02-15 2021-02-26 Bioverativ Therapeutics Inc Optimized factor viii gene
AU2014217831A1 (en) 2013-02-16 2015-07-16 Albumedix Ltd. Pharmacokinetic animal model
EP2968498A4 (en) 2013-03-15 2016-09-07 Biogen Ma Inc Factor ix polypeptide formulations
EP3013358A4 (en) 2013-06-28 2017-03-22 Biogen MA Inc. Thrombin cleavable linker with xten and its uses thereof
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
CN116731201A (en) 2014-01-10 2023-09-12 比奥贝拉蒂治疗公司 Factor VIII chimeric proteins and uses thereof
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
EA201700181A1 (en) 2014-10-14 2017-09-29 Галозим, Инк. COMPOSITIONS OF ADENOSINDEMINASE-2 (ADA-2), THEIR OPTIONS AND METHODS OF USE
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
EP3331608A4 (en) 2015-08-03 2019-05-01 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
CN108137674B (en) 2015-08-20 2022-12-06 阿尔布梅迪克斯医疗有限公司 Albumin variants and conjugates
CN115960249A (en) 2015-10-02 2023-04-14 银溪制药股份有限公司 Bispecific therapeutic proteins for tissue repair
CN105254766B (en) * 2015-10-26 2018-10-16 中国航天员科研训练中心 Application of the Mecano growth factor MGF E domain peptides in regulation and control memory related gene and miRNA expression
AU2017214378B2 (en) 2016-02-01 2023-05-04 Bioverativ Therapeutics Inc. Optimized Factor VIII genes
CA3022119A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US20210333279A1 (en) 2016-11-04 2021-10-28 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
MA46968A (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc METHODS FOR INDUCTION OF IMMUNE TOLERANCE TO COAGULATION FACTORS
KR20190090827A (en) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. How Chimeric Coagulation Factors Can Be Used to Treat Hemophilic Arthrosis
WO2018112362A1 (en) 2016-12-16 2018-06-21 Biogen Ma Inc. Stabilized proteolytically activated growth differentiation factor 11
MX2019009063A (en) 2017-01-31 2019-10-21 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same.
JP2020517657A (en) * 2017-04-20 2020-06-18 ノヴォ ノルディスク アー／エス Purification method of albumin fusion protein
EP3665289A1 (en) 2017-08-09 2020-06-17 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
WO2019152692A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
US20200069817A1 (en) 2018-08-09 2020-03-05 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
JP2022514465A (en) 2018-12-06 2022-02-14 バイオベラティブ セラピューティクス インコーポレイテッド Use of lentiviral vector expressing factor IX
TW202126284A (en) 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 Lentiviral vector formulations
WO2022030580A1 (en) * 2020-08-06 2022-02-10 国立大学法人宮崎大学 Novel long-acting adrenomedullin derivative, method for producing same and pharmaceutical use thereof
JP2024056667A (en) * 2022-10-11 2024-04-23 Ｊｃｒファーマ株式会社 Fusion protein of serum albumin and a biologically active protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003296A2 (en) * 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
PT1463751E (en) * 2001-12-21 2013-08-26 Human Genome Sciences Inc Albumin fusion proteins
PL1729795T3 (en) * 2004-02-09 2016-08-31 Human Genome Sciences Inc Albumin fusion proteins
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs

Also Published As

Publication number Publication date
ECSP088262A (en) 2008-05-30
CA2618476A1 (en) 2007-02-22
KR20080071119A (en) 2008-08-01
BRPI0614761A2 (en) 2009-05-19
EP1924596A2 (en) 2008-05-28
WO2007021494A3 (en) 2007-07-26
WO2007021494A2 (en) 2007-02-22
JP2009504157A (en) 2009-02-05
EP1924596A4 (en) 2009-07-29
NO20081233L (en) 2008-05-09
TNSN08064A1 (en) 2009-07-14
MX2008001865A (en) 2008-04-15
IL189246A0 (en) 2008-08-07
AU2006280312A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
MA29836B1 (en) FUSION PROTEINS WITH ALBUMIN
EP1841426A4 (en) Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of alzheimer's disease
MX2009002816A (en) Albumin fusion proteins.
MA31862B1 (en) Antiseptic antibodies and their uses
EA200870019A1 (en) LACTAMIC CONNECTIONS AND METHODS OF THEIR APPLICATION
IL195338A (en) Antibody comprising an fc variant comprising d or e amino acid substitution at position 239 and pharmaceutical composition and use thereof
DE602005021072D1 (en) ADZYME AND ITS USES
ATE433973T1 (en) AZOLYLAMINOAZINES AS INHIBITORS OF PROTEIN KINASES
MA30085B1 (en) TREATMENT OF TYPE 2 DIABETES WITH AN ASSOCIATION OF DPIV INHIBITOR AND METFORMIN OR THIAZOLIDINEDIONE
MA30337B1 (en) ANTIBODY
DE602004014117D1 (en) THIAZOLE FOR USE AS INHIBITORS OF PROTEIN KINASES
ATE483692T1 (en) 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS BETA-SECRETASE (BACE) INHIBITORS
NO20054957L (en) Substituted carboxylic acids
WO2005077042A3 (en) Albumin fusion proteins
ATE466580T1 (en) AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITORS
ATE468336T1 (en) AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITORS
ATE365733T1 (en) COMPOSITIONS USEFUL AS PROTEIN KINASE INHIBITORS
EA200802054A1 (en) ENZYME INHIBITORS
NO20053855L (en) 1-Phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases.
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
MA30041B1 (en) IMMUNOGLOBULIN
HUP0302384A2 (en) Compositions of biochemical compounds involved in bioenergy metabolism of cells and method of use
WO2008127680A3 (en) Diagnosis and treatment of diseases caused by misfolded proteins
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
MA34225B1 (en) STABLE PREPARATION OF MIA / CD-RAP